FerroptoCure Received “WE AT AWARD 2025” at WE AT CHALLENGE 2025

FerroptoCure Inc. (Head Office: [City, Prefecture], Japan; CEO: Yuji Otsuki) is pleased to announce that it has received the WE AT AWARD 2025 in the Human Well-being track at “WE AT CHALLENGE 2025,” a pitch contest organized by the general incorporated association WE AT.

WE AT CHALLENGE 2025 Announces Award Winners at One of Asia’s Largest Well-being Innovation Events - WE AT

The general incorporated association WE AT, which aims to advance the global well-being industry through solutions to societal challenges, hosted “WE AT

WE AT

WE AT aims to develop the well-being industry by addressing global social challenges and building a new innovation ecosystem that connects academia, government, industry, and investors.
WE AT CHALLENGE 2025 is a pitch contest aspiring to become one of the largest well-being events in Asia, which this year attracted nearly 600 applications from 32 countries worldwide, culminating in pitches delivered by 16 selected finalist teams.

Within this contest, FerroptoCure was selected as one of the finalists in the Human Well-being track and was honored with the WE AT AWARD 2025.
Through the development of innovative ferroptosis-targeting oncology therapeutics, FerroptoCure will continue to strive to improve clinical outcomes for cancer patients and to contribute to enhanced well-being and a more sustainable healthcare system.